Patenting of DNA Will Continue - Patentability of Genes

by K&L Gates LLP

The availability of patent protection for human genes continues to fuel debate around the world.

Patent offices have cumulatively granted thousands of patents directed to isolated nucleic acids, deoxyribonucleic acid (DNA) and genes. The commonly held view in most jurisdictions has been that, while naturally occurring material including nucleic acids, DNA and genes, is not eligible for patent protection, isolated, modified or altered versions of such naturally occurring material are considered patentable.

The question as to whether isolated forms of naturally occurring compounds that lack artificial generation or modification should continue to be patentable, has been addressed in the United States and recently re-addressed in Australia. However, it should be noted that DNA patenting in the last decade has advanced beyond the mere isolation of natural genes. Furthermore, the publication of the complete human genome sequence over a decade ago, has long precluded the patentability of isolated genes per se for novelty reasons. Therefore, these legal decisions questioning the patentability of isolated genes will have little impact on DNA patenting and will only impact older patent cases that have expired or are close to expiry.

The validity of gene patents owned by Myriad Genetics directed to breast and ovarian cancer, marker genes BRCA1 and BRCA2, has been the basis of the recent legal rulings directed to the patentability of gene debate in both the United States and Australia.

United States

The Court of Appeals for the Federal Circuit had previously upheld the patentability of isolated nucleic acid molecules. However, on 13 June 2013, the U.S. Supreme Court ruled that Myriad's isolated BRCA genes are not patentable. The rationale for this decision, made by Justice Clarence Thomas, was that the discovery of a useful naturally occurring gene is important, but merely separating that gene from its surrounding genetic material is not an act of invention. This decision was probably heavily influenced by mounting opinion by medical groups that companies, like Myriad, should not be allowed to use its gene patents to sue clinics and prevent others from doing independent tests to diagnose serious medical conditions like breast cancer.

The end result of this decision means that, in the United States, more companies may develop alternative BRCA1 and BRCA2 tests and the public may have greater access to such genetic testing. The decision also impacts the validity and enforceability of existing granted patents that rely on claims directed to isolated, naturally occurring, genes. However, it is important to note that the decision does not impact the patentability of nucleic acid molecules that have been modified or don't occur in nature, such as lab generated DNA (cDNA) which remains patentable in the United States. In addition, the extent that the decision will impact Myriad and other companies may depend on the scope and wording of the gene patent claims that have been granted. For example, companies like Myriad may still have valid patent claims directed to cDNA and method claims that allow for certain exclusive rights to continue enforcing their specific diagnostic testing for breast cancer. Going forward, diagnostic patents based on genetic testing will need to continue to rely more on patenting artificial primers, probes, and innovative testing methods or methods of manipulating genes for diagnostic screens to obtain valid gene related patent claims in the United States.


In Australia, past decisions from both senate enquiries and the Federal Court of Australia have supported maintaining the patentability of isolated nucleic acid molecules. It was held that, although naturally occurring DNA and ribonucleic acid (RNA) as they exist inside the cells of the human body cannot be the subject of a valid patent, the Myriad disputed claims did not cover naturally occurring DNA but isolated and extracted DNA from cells of a human body that was regarded as patentable. However, the Australia Federal Court decision was appealed in March this year and submissions for this case will include consideration of the U.S. Supreme Court ruling. The Australian appeal judgment is yet to be finalised. Will the Australian courts mirror the opposing decision of the United States? Presently, countries such as Australia, Europe, Canada, India and Japan are harmonized with regard to permitting the patenting of human genes provided the genes are isolated and the patent application teaches useful applications of the isolated genes. Therefore, the United States currently stands alone with the Supreme Court decision that isolated forms of naturally occurring DNA sequences cannot be patented.

Will the Myriad Cases Have an Impact on Gene Patenting?

If the Australian appeal decision follows the U.S. ruling, then it will impact the validity and enforceability of past granted gene patents directed to isolated genes. However, even if the Australian Full Federal Court rules against Myriad Myriad's isolated BRCA genes, it will certainly not be the end of patenting of DNA subject matter.

In the last decade, biotechnology developments have been primarily based on the generation of modified or artificial DNA and recombinant proteins expressed from cDNA sequences that do not occur in nature. Therefore, it is likely that the Australian appeal decision will not hugely impact the patentability of modified or altered forms of genes, recombinant DNA, plasmids and methods of generating or application of such DNA compounds. Applicants are still likely to be able to obtain patent protection for DNA based molecules where the claimed molecule can be distinguished from the native molecule.

Association for Molecular Pathology v. Myriad Genetics, 569 U.S. 12-398 (2013)
Cancer Voices Australia v Myriad Genetics Inc [2013] FCA 65
Yvonne D'Arcy v Myriad Genetics Inc & Anor filed Notice of Appeal 04-Mar-2013

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© K&L Gates LLP | Attorney Advertising

Written by:

K&L Gates LLP

K&L Gates LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.